ARCA biopharma, Inc. (NASDAQ: ABIO) is dedicated to the development of genetically-targeted therapies for cardiovascular diseases. The company’s lead product candidate, bucindolol, is an investigational, pharmacologically unique beta-blocker and mild vasodilator being developed to treat atrial fibrillation. ARCA has identified common genetic variations that it believes predict individual patient response to bucindolol, giving it the potential to be the first genetically-targeted preventative treatment for atrial fibrillation. The U.S. Food and Drug Administration has designated the investigation of bucindolol for the treatment of atrial fibrillation as a fast track development program. For more information, visit the company’s website at www.arcabiopharma.com.